BeOne Medicines (BEIGF) Gross Profit (2017 - 2026)

BeOne Medicines (BEIGF) has 10 years of Gross Profit data on file, last reported at $1.3 billion in Q1 2026.

• Gross Profit for Q1 2026 came in at $1.3 billion, up 41.37% year-over-year; the trailing twelve-month figure through Mar 2026 was $5.1 billion (up 43.11% YoY), and the FY2025 annual result was $4.7 billion, up 45.34% from the prior year.
• Gross Profit fell to $1.3 billion in Q1 2026 per BEIGF's latest filing, from $1.4 billion in the prior quarter.
• Over five years, Gross Profit peaked at $1.4 billion in Q4 2025 and troughed at $241.4 million in Q1 2022.
• A 5-year average of $732.1 million and a median of $685.0 million in 2023 frame the typical range for Gross Profit.
• On a YoY basis, Gross Profit climbed as much as 137.76% in 2022 and fell as far as 57.89% in 2022.
• A 5-year view of Gross Profit shows it stood at $306.6 million in 2022, then soared by 72.41% to $528.6 million in 2023, then jumped by 82.99% to $967.3 million in 2024, then surged by 40.16% to $1.4 billion in 2025, then decreased by 0.7% to $1.3 billion in 2026.
• Business Quant data shows BEIGF's Gross Profit at $1.3 billion in Q1 2026, $1.4 billion in Q4 2025, and $1.2 billion in Q3 2025.